newsGilead data lends insight into transforming HIV prevention landscape13 November 2024 | By Catherine Eckford (European Pharmaceutical Review)Results suggest that the small molecule treatment could be an alternative to current medication that aims to prevent HIV infection and which require more frequent dosing.
newsGilead small molecule demonstrates strong capability for HIV prevention21 June 2024 | By Catherine Eckford (European Pharmaceutical Review)According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
newsSimplified HIV treatment options effective in major trial23 February 2023 | By Catherine Eckford (European Pharmaceutical Review)The world‘s first international trial into second-line HIV therapy has shown two simplified treatments are at least as effective as standard of care.
newsGilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability24 July 2017 | By Steve Bremer (European Pharmaceutical Review)Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance
